Paper Details

  1. Home
  2. Paper Details

Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial.

Author: AlsinaMelissa, AndersonKenneth C, Ben-YehudaDina, BladéJoan, BoccadoroMario, BoralAnthony, CavenaghJamie, DaltonWilliam, EsseltineDixie-Lee, FaconThierry, GoldschmidtHartmut, HarousseauJean-Luc, IrwinDavid, JakubowiakAndrzej, LacyMartha, LonialSagar, MiguelJesus San, RajkumarS Vincent, ReeceDonna, RichardsonPaul G, SchenkeinDavid, SchusterMichael, SonneveldPieter, StadtmauerEdward

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Bortezomib is a promising treatment for relapsed multiple myeloma patients, showing longer time to progression, higher response rate, and improved survival compared to high-dose dexamethasone.
Paper Details　
Original Abstract of the Article :
Initial analysis of the Assessment of Proteasome Inhibition for Extending Remissions (APEX) trial of relapsed multiple myeloma patients showed significantly longer time to progression, higher response rate, and improved survival with single-agent bortezomib versus high-dose dexamethasone. In this up...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1182/blood-2006-08-036947

データ提供：米国国立医学図書館（NLM）

Bortezomib: A Beacon of Hope in the Desert of Relapsed Multiple Myeloma

Relapsed multiple myeloma, a cancer of the plasma cells in bone marrow, can be a challenging journey through the desert of disease. This study, like a camel navigating the treacherous sands, evaluates the effectiveness of bortezomib, a proteasome inhibitor, in the treatment of relapsed multiple myeloma. Researchers analyzed data from a phase 3 clinical trial, comparing the outcomes of patients treated with single-agent bortezomib to those treated with high-dose dexamethasone. The study found that bortezomib significantly prolonged time to progression, improved response rates, and enhanced overall survival compared to dexamethasone. Moreover, the study observed continued improvement in response quality with extended bortezomib therapy.

A Path Forward in the Desert of Multiple Myeloma

This research provides valuable insights into the efficacy of bortezomib in treating relapsed multiple myeloma. The study's findings suggest that bortezomib can offer a significant advantage in terms of response rates, time to progression, and overall survival compared to traditional treatments. However, it's important to note that individual responses to treatment can vary, and careful monitoring is crucial.

Navigating the Desert of Cancer

Multiple myeloma is a complex and challenging disease, and managing it effectively requires a multi-faceted approach. Working closely with a healthcare professional to develop an individualized treatment plan, including medications, supportive care, and lifestyle modifications, is essential for navigating the desert of cancer.

Dr. Camel's Conclusion

Bortezomib, a new weapon in the fight against relapsed multiple myeloma, offers a beacon of hope in the desert of disease. This study, like a camel finding a hidden oasis, provides valuable insights into the potential of this medication, offering a glimmer of hope for individuals battling this challenging cancer.
Date :
  1. Date Completed 2008-01-09
  2. Date Revised 2022-03-21
Further Info :

Pubmed ID

17690257

DOI: Digital Object Identifier

10.1182/blood-2006-08-036947

Related Literature

Article Analysis
・Effective treatment of multiple myeloma
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.